guest ::
| Home > Publications database > Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. |
| Home > Publications database > Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. |
| Journal Article | DKFZ-2025-01472 |
; ; ; ; ; ; ; ; ; ; ;
2025
Elsevier
Amsterdam
This record in other databases: 
Please use a persistent id in citations: doi:10.1016/j.ymthe.2025.07.014
Abstract: Personalized treatment has become a realistic option for tumor patients, accelerated by significantly reduced sequencing costs of tumor genomes and advances in vaccine formulations. The druggability of cancer neo-antigens caused by individual mutations is centered in this effort. We here use an AAV-based VLP platform to compose a neo-antigen specific protein vaccine that is effective in a murine prevention and treatment setting. Furthermore, we show that CD4+ T cell responses that are provided by the AAV capsid are crucial for an effective murine melanoma treatment. To uncover the optimal composition of a peptide vaccine we de-linked MHC-II helper peptides from the capsid and formulated an efficient neo-antigen specific vaccine, which showed the independence of CD4+ T cell response from tumor sequences. The findings are supported by clinical data of neo-antigen vaccinated tumor patients. Our results punctuate on the significance of MHC-II epitopes for CD8+ T cell responses and suggest a future use of AAVLPs as neo-epitope vaccines in personalized cancer treatments.
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
